COCA
(Colorectal Cancer)
qPCR SNP Detection Kit
Description
Analysed gene is responsible for production of a protein that inhibits the growth of colon cancer by controlling the frequency of cell division and protecting against the unimpeded growth of cancer cells. Colorectal Cancer is the second most common cancer affecting humanity.
REF. NUMBER
755SNP451pcc
PREDISPOSITION
Colorectal Cancer
ANALYSED GENES
APC, CRAC1
IDENTIFIED POLYMORPHISMS
rs1801155, rs4779584
KIT CONTENTS
2 × Nuclease-Free Water
2 × 2xSNP MasterMix
2 × Oligos Set
2 × Positive Control Set
QUANTITY
100 rxns
STORAGE CONDITIONS
-25°C to -15°C
CERTIFICATES
More Information
Did you know...?
Colorectal cancer is the third most common cancer in men in the world and the second in women. This type of cancer is the second most common cause of death from cancer. It is estimated that by the year 2035, the total number of deaths from rectal and colon cancer will increase by 60% and 71.5%, respectively. Among other risk factors like: obesity, unhealthy diet, excessive alcohol consumption and smoking, genetic predisposition is similarly important.
What may happen?
APC and CRAC1 mutations are frequent in patients with colorectal cancer. Mutation in APC gene increases the risk of familial adenomatous polyposis coli (FAP). During the course of this disease the patient’s colon starts to develop polyps and many of these colon polyps evolve into cancer. The other disease – hereditary mixed polyposis syndrome (HMPS) is associated with single nucleotide polymorphism in the CRAC1 region. Similar to FAP, the patient’s colon begins to develop polyps and many of these evolve into cancer over time.
How the test is performed?
The APC and CRAC1 genes are DNA fragments containing instructions for building proteins that are involved in the development of colorectal cancer. The test performed focuses on two specific positions in the gene where changes (mutations) can occur. The real-time PCR method is used for gene analysis. It allows for a fast and accurate determination of the patient’s genotype.
How will the client benefit?
The offered test provides information about the patient’s polymorphism without the need for time-consuming sequencing. The preparation of the reaction mixture is simple and requires a small amount of reagents and test material. An additional advantage is the same thermal cycling profile for both genes, which allows for simultaneous analysis using the same device and obtaining results in a short time. The ease of interpretation of the results based on matrix in IFU product allows for the efficient determination of the patient’s genotype and the risk of developing the disease. The patient will receive a result with a precise determination of his genotype along with recommendations.
Why is it worth doing a genetic test?
Malignant neoplasms are the so-called diseases of civilization, which are often rooted in an unhealthy lifestyle. Processed products, lack of physical activity, stimulants such as alcohol or cigarettes are the norm in developed countries. The increasing awareness of people about diseases encourages them to perform genetic tests, which is why the demand for genetic predisposition tests is constantly growing, especially in the case of such serious diseases as cancer.
What can be done after the test result?
In the case of an unfavorable variant of the gene, it is important to follow the recommendations and consult a doctor. It should be remembered that a normal genotype does not exclude the disease. The great potential of genetic testing makes it possible to predict many diseases and gives a chance to take action to improve health.